New Jersey A1207 mandates Medicaid coverage for ovulation enhancing drugs and related medical services for beneficiaries aged 21-44 experiencing.
New Jersey A1207 amends the state's Medicaid program to require coverage for ovulation enhancing drugs and associated medical services for beneficiaries aged 21-44 who are experiencing infertility. The bill defines infertility based on the duration of unprotected intercourse without pregnancy. Covered medical services include office visits, hysterosalpingograms, pelvic ultrasounds, and blood testing. The coverage is limited to three cycles of treatment per beneficiary's lifetime.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.